|

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

RECRUITINGSponsored by Ausper Biopharma Co., Ltd.
Actively Recruiting
SponsorAusper Biopharma Co., Ltd.
Started2025-08-28
Est. completion2028-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07146100

Summary

This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Capable of giving informed consent.
* Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.

Exclusion Criteria:

* Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.
* Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.

Conditions2

Chronic Hepatitis bLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.